BioSpace News Archive

Novan, Inc., announced that it will report its second quarter 2021 financial results on Thursday, August 12th.

Rhythm Pharmaceuticals, Inc. announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8 a.m. ET.

Mesa Laboratories, Inc. reported results for its first fiscal quarter.

Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Portage Biotech Inc. announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell agonist IMM60 developed for the treatment of solid tumors.

Catalyst Biosciences, Inc. announced its operating and financial results for the second quarter ended June 30, 2021, and provided a corporate update.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its second quarter 2021 financial results on Thursday, August 12, 2021.

Immutep Limited, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, announced it has successfully reached its target of 20 activated clinical trial sites in the Phase 2b portion of the VOICE trial.

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord Genuity’s 41st Annual Growth Conference on Wednesday, August 11, 2021 at 2:30 p.m. ET.